Jing-Yi Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jing-Yi Tang has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Zhong-Yan Zhou
Longhua Hospital Shanghai University of Traditional Chinese Medicine Shanghai P.R. China
12 shared publications Jing Zhang
Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, PR China
7 shared publications- Wai-Rong Zhao
Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
7 shared publications Wai-Rong Zhao
Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, PR China
6 shared publicationsWen-Ting Shi
Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
5 shared publications- Xin-Lin Chen
Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
5 shared publications
Latest Publications
- 27 April 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1881 (4) , 189598
The pathology and diagnosis of cancer cachexia and a treatment insight from natural products: A review
- 27 April 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1881 (4) , 189598
The pathology and diagnosis of cancer cachexia and a treatment insight from natural products: A review
- Open Access
- 8 September 2025
- Published by Elsevier in Phytomedicine
- Vol. 148, 157244
Salviae Miltiorrhizae Radix et Rhizoma protects against doxorubicin-induced cardiotoxicity: A systematic review
- 8 September 2025
- Published by Elsevier in Phytomedicine
- Vol. 148, 157244
Open AccessSalviae Miltiorrhizae Radix et Rhizoma protects against doxorubicin-induced cardiotoxicity: A systematic review
- Open Access
- 6 April 2025
- Published by Elsevier in Life Sciences
- Vol. 372, 123614
The role of branched-chain amino acids in cardio-oncology: A review
- 6 April 2025
- Published by Elsevier in Life Sciences
- Vol. 372, 123614
Open AccessThe role of branched-chain amino acids in cardio-oncology: A review
- Open Access
- 1 April 2025
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 21, 217-228
Correlational Analysis of Resistant Hypertension with Diabetes Mellitus, Chronic Kidney Disease, and the Interplay of Sodium, Calcium, Magnesium, and Phosphorus
Objective: To analyze the relationship between resistant hypertension (RH) and hypertension, diabetes mellitus, chronic kidney disease, sodium, calcium, magnesium, phosphorus. Methods: A total of 475 patients with hypertension admitted to Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from January 2021 to December 2023 were divided into hypertension group (HT group) and resistant hypertension group (RH group). We compared the differences between these two groups, and analyzed the influencing factors of RH, as well as the correlation between RH and the course of hypertension, diabetes mellitus, chronic kidney disease, and levels of sodium, calcium, magnesium and phosphorus. Results: Compared with HT group, RH group had a significantly higher blood pressure (P < 0.05), longer duration of hypertension, diabetes mellitus, and chronic kidney disease (P < 0.01) and a higher proportion of combined chronic kidney disease (P = 0.006). The duration of hypertension, serum sodium ion concentration (≥ 142.00 mmol/L), calcium ion concentration (2.19 to < 2.30 mmol/L), and 24h urinary phosphorus ion level were independent influencing factors of RH (P < 0.05). Conclusion: For hypertension patients with diabetes mellitus or chronic kidney disease, the risk of RH is significantly higher. The risk of RH may be lower in patients with blood sodium < 142.00 mmol/L, blood calcium > 2.29 mmol/L, 24h urine sodium and magnesium ions of 116.52 and 2.69 mmol, respectively, and higher 24h urine phosphorus ions.
- 1 April 2025
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 21, 217-228
Open AccessCorrelational Analysis of Resistant Hypertension with Diabetes Mellitus, Chronic Kidney Disease, and the Interplay of Sodium, Calcium, Magnesium, and Phosphorus
Objective: To analyze the relationship between resistant hypertension (RH) and hypertension, diabetes mellitus, chronic kidney disease, sodium, calcium, magnesium, phosphorus. Methods: A total of 475 patients with hypertension admitted to Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from January 2021 to December 2023 were divided into hypertension group (HT group) and resistant hypertension group (RH group). We compared the differences between these two groups, and analyzed the influencing factors of RH, as well as the correlation between RH and the course of hypertension, diabetes mellitus, chronic kidney disease, and levels of sodium, calcium, magnesium and phosphorus. Results: Compared with HT group, RH group had a significantly higher blood pressure (P < 0.05), longer duration of hypertension, diabetes mellitus, and chronic kidney disease (P < 0.01) and a higher proportion of combined chronic kidney disease (P = 0.006). The duration of hypertension, serum sodium ion concentration (≥ 142.00 mmol/L), calcium ion concentration (2.19 to < 2.30 mmol/L), and 24h urinary phosphorus ion level were independent influencing factors of RH (P < 0.05). Conclusion: For hypertension patients with diabetes mellitus or chronic kidney disease, the risk of RH is significantly higher. The risk of RH may be lower in patients with blood sodium < 142.00 mmol/L, blood calcium > 2.29 mmol/L, 24h urine sodium and magnesium ions of 116.52 and 2.69 mmol, respectively, and higher 24h urine phosphorus ions.
- Open Access
- 23 October 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (10) , e9507
A case report of cardiac rehabilitation in coronary artery aneurysm combined with acute ST segment elevation myocardial infarction
Key Clinical Message: Coronary artery aneurysm (CAA), marked by diffuse or localized dilation of artery, can cause life‐threatening complications in acute coronary syndrome. This report presents a case of CAA combined with acute ST‐segment elevation myocardial infarction, successfully treated with cardiac rehabilitation exercise therapy, offering insights for clinical practice.
- 23 October 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (10) , e9507
Open AccessA case report of cardiac rehabilitation in coronary artery aneurysm combined with acute ST segment elevation myocardial infarction
Key Clinical Message: Coronary artery aneurysm (CAA), marked by diffuse or localized dilation of artery, can cause life‐threatening complications in acute coronary syndrome. This report presents a case of CAA combined with acute ST‐segment elevation myocardial infarction, successfully treated with cardiac rehabilitation exercise therapy, offering insights for clinical practice.
- Open Access
- 10 October 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (10) , 2301
Intracellular Iron Deficiency and Abnormal Metabolism, Not Ferroptosis, Contributes to Homocysteine-Induced Vascular Endothelial Cell Death
Background/Objectives: Homocysteine (Hcy) and iron are factors co-related with the progression of cardiovascular diseases. The vascular endothelium is an important barrier for physiological homeostasis, and its impairment initiates cardiovascular injury. However, the mechanism underlying Hcy-caused vascular endothelial cell injury and the participation of iron are not fully elucidated. This study aims to investigate the Hcy-induced vascular endothelial injury and iron metabolism dysfunction as well as the underlying molecular mechanism. Methods: Human umbilical vein endothelial cells (HUVECs) were employed as the experimental model to examine the Hcy-induced endothelial injury and its underlying mechanism via various biochemical assays. Results: Hcy suppressed the cell viability and proliferation and caused cell death in a concentration-dependent manner. Hcy induced cell cycle arrest, apoptosis, and autophagy as well as impairment of intracellular energy metabolism. Hcy disrupted the intracellular antioxidant system and mitochondrial function by increasing intracellular ROS, MDA and mitochondrial content, and decreasing the SOD activity and mitochondrial membrane potential. Hcy significantly reduced the GSH-Px activity along with the accumulation of intracellular GSH in a concentration-dependent manner. Ferroptosis inhibitors, Ferrostatin-1 (Fer-1), and Deferoxamine (DFO) significantly decreased the Hcy-caused cytotoxicity accompanied by a reduction in dysregulated mitochondria content, but only DFO ameliorated the elevation of intracellular ROS, and neither Fer-1 nor DFO affected the Hcy-caused reduction in intracellular ATP. In addition, Hcy decreased the intracellular concentration of iron, and supplementing Hcy with various concentrations of Fe3+ increased the cell viability and decreased the LDH release in a concentration-dependent manner. Hcy dramatically decreased the mRNA expression level of transferrin receptor while increasing the mRNA expression levels of transferrin, ferritin light chain, ferritin heavy chain, ferroportin, and SLC7A11. Moreover, Hcy suppressed the protein expression of phospho-Akt, phospho-mTOR, Beclin-1, LC3A/B, Nrf2, HO-1, phospho-MEK1/2, phospho-ERK1/2, and Caspase-3 in concentration- and time-dependent manners. Conclusions: Hcy-induced vascular endothelial injury is likely to be associated with apoptosis and autophagy, but not ferroptosis. The key underlying mechanisms are involved in the disruption of the intracellular antioxidant system and iron metabolism via regulation of PI3K/Akt/mTOR, MAPKs, Nrf2/HO-1, and iron metabolism.
- 10 October 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (10) , 2301
Open AccessIntracellular Iron Deficiency and Abnormal Metabolism, Not Ferroptosis, Contributes to Homocysteine-Induced Vascular Endothelial Cell Death
Background/Objectives: Homocysteine (Hcy) and iron are factors co-related with the progression of cardiovascular diseases. The vascular endothelium is an important barrier for physiological homeostasis, and its impairment initiates cardiovascular injury. However, the mechanism underlying Hcy-caused vascular endothelial cell injury and the participation of iron are not fully elucidated. This study aims to investigate the Hcy-induced vascular endothelial injury and iron metabolism dysfunction as well as the underlying molecular mechanism. Methods: Human umbilical vein endothelial cells (HUVECs) were employed as the experimental model to examine the Hcy-induced endothelial injury and its underlying mechanism via various biochemical assays. Results: Hcy suppressed the cell viability and proliferation and caused cell death in a concentration-dependent manner. Hcy induced cell cycle arrest, apoptosis, and autophagy as well as impairment of intracellular energy metabolism. Hcy disrupted the intracellular antioxidant system and mitochondrial function by increasing intracellular ROS, MDA and mitochondrial content, and decreasing the SOD activity and mitochondrial membrane potential. Hcy significantly reduced the GSH-Px activity along with the accumulation of intracellular GSH in a concentration-dependent manner. Ferroptosis inhibitors, Ferrostatin-1 (Fer-1), and Deferoxamine (DFO) significantly decreased the Hcy-caused cytotoxicity accompanied by a reduction in dysregulated mitochondria content, but only DFO ameliorated the elevation of intracellular ROS, and neither Fer-1 nor DFO affected the Hcy-caused reduction in intracellular ATP. In addition, Hcy decreased the intracellular concentration of iron, and supplementing Hcy with various concentrations of Fe3+ increased the cell viability and decreased the LDH release in a concentration-dependent manner. Hcy dramatically decreased the mRNA expression level of transferrin receptor while increasing the mRNA expression levels of transferrin, ferritin light chain, ferritin heavy chain, ferroportin, and SLC7A11. Moreover, Hcy suppressed the protein expression of phospho-Akt, phospho-mTOR, Beclin-1, LC3A/B, Nrf2, HO-1, phospho-MEK1/2, phospho-ERK1/2, and Caspase-3 in concentration- and time-dependent manners. Conclusions: Hcy-induced vascular endothelial injury is likely to be associated with apoptosis and autophagy, but not ferroptosis. The key underlying mechanisms are involved in the disruption of the intracellular antioxidant system and iron metabolism via regulation of PI3K/Akt/mTOR, MAPKs, Nrf2/HO-1, and iron metabolism.
- Open Access
- 9 May 2024
- Published by Elsevier in Phytomedicine
- Vol. 130, 155717
Qiangxinyin formula protects against isoproterenol-induced cardiac hypertrophy
- 9 May 2024
- Published by Elsevier in Phytomedicine
- Vol. 130, 155717
Open AccessQiangxinyin formula protects against isoproterenol-induced cardiac hypertrophy
- Open Access
- 14 December 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 158, 114137
Sodium tanshinone IIA sulfonate protects against hyperhomocysteine-induced vascular endothelial injury via activation of NNMT/SIRT1-mediated NRF2/HO-1 and AKT/MAPKs signaling in human umbilical vascular endothelial cells
- 14 December 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 158, 114137
Open AccessSodium tanshinone IIA sulfonate protects against hyperhomocysteine-induced vascular endothelial injury via activation of NNMT/SIRT1-mediated NRF2/HO-1 and AKT/MAPKs signaling in human umbilical vascular endothelial cells
- Open Access
- 30 November 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1037341
Targeting glycolysis in non-small cell lung cancer: Promises and challenges
Metabolic disturbance, particularly of glucose metabolism, is a hallmark of tumors such as non-small cell lung cancer (NSCLC). Cancer cells tend to reprogram a majority of glucose metabolism reactions into glycolysis, even in oxygen-rich environments. Although glycolysis is not an efficient means of ATP production compared to oxidative phosphorylation, the inhibition of tumor glycolysis directly impedes cell survival and growth. This review focuses on research advances in glycolysis in NSCLC and systematically provides an overview of the key enzymes, biomarkers, non-coding RNAs, and signaling pathways that modulate the glycolysis process and, consequently, tumor growth and metastasis in NSCLC. Current medications, therapeutic approaches, and natural products that affect glycolysis in NSCLC are also summarized. We found that the identification of appropriate targets and biomarkers in glycolysis, specifically for NSCLC treatment, is still a challenge at present. However, LDHB, PDK1, MCT2, GLUT1, and PFKM might be promising targets in the treatment of NSCLC or its specific subtypes, and DPPA4, NQO1, GAPDH/MT-CO1, PGC-1α, OTUB2, ISLR, Barx2, OTUB2, and RFP180 might be prognostic predictors of NSCLC. In addition, natural products may serve as promising therapeutic approaches targeting multiple steps in glycolysis metabolism, since natural products always present multi-target properties. The development of metabolic intervention that targets glycolysis, alone or in combination with current therapy, is a potential therapeutic approach in NSCLC treatment. The aim of this review is to describe research patterns and interests concerning the metabolic treatment of NSCLC.
- 30 November 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1037341
Open AccessTargeting glycolysis in non-small cell lung cancer: Promises and challenges
Metabolic disturbance, particularly of glucose metabolism, is a hallmark of tumors such as non-small cell lung cancer (NSCLC). Cancer cells tend to reprogram a majority of glucose metabolism reactions into glycolysis, even in oxygen-rich environments. Although glycolysis is not an efficient means of ATP production compared to oxidative phosphorylation, the inhibition of tumor glycolysis directly impedes cell survival and growth. This review focuses on research advances in glycolysis in NSCLC and systematically provides an overview of the key enzymes, biomarkers, non-coding RNAs, and signaling pathways that modulate the glycolysis process and, consequently, tumor growth and metastasis in NSCLC. Current medications, therapeutic approaches, and natural products that affect glycolysis in NSCLC are also summarized. We found that the identification of appropriate targets and biomarkers in glycolysis, specifically for NSCLC treatment, is still a challenge at present. However, LDHB, PDK1, MCT2, GLUT1, and PFKM might be promising targets in the treatment of NSCLC or its specific subtypes, and DPPA4, NQO1, GAPDH/MT-CO1, PGC-1α, OTUB2, ISLR, Barx2, OTUB2, and RFP180 might be prognostic predictors of NSCLC. In addition, natural products may serve as promising therapeutic approaches targeting multiple steps in glycolysis metabolism, since natural products always present multi-target properties. The development of metabolic intervention that targets glycolysis, alone or in combination with current therapy, is a potential therapeutic approach in NSCLC treatment. The aim of this review is to describe research patterns and interests concerning the metabolic treatment of NSCLC.
- Open Access
- 20 July 2022
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 297, 115547
Tribulus terrestris L. extract ameliorates atherosclerosis by inhibition of vascular smooth muscle cell proliferation in ApoE−/− mice and A7r5 cells via suppression of Akt/MEK/ERK signaling
- 20 July 2022
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 297, 115547
Open AccessTribulus terrestris L. extract ameliorates atherosclerosis by inhibition of vascular smooth muscle cell proliferation in ApoE−/− mice and A7r5 cells via suppression of Akt/MEK/ERK signaling